Literature DB >> 22516574

Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice?

J M Hofstra1, J F Wetzels.   

Abstract

The identification of circulating autoantibodies against the M-type phospholipase A₂ receptor (anti-PLA₂R) in patients with idiopathic membranous nephropathy (iMN) has been a major discovery. Anti-PLA₂R can be measured by a commercially available test. It is suggested that measurement of anti-PLA₂R will change the diagnostic strategy in patients with nephrotic syndrome and may guide treatment in patients with iMN. We review the available evidence and caution against the immediate injudicious use of the assay in routine clinical practice.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22516574

Source DB:  PubMed          Journal:  Neth J Med        ISSN： 0300-2977            Impact factor:   1.422


  23 in total

1.  Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy.

Authors:  Marieke J H Coenen; Julia M Hofstra; Hanna Debiec; Horia C Stanescu; Alan J Medlar; Bénédicte Stengel; Anne Boland-Augé; Johanne M Groothuismink; Detlef Bockenhauer; Steve H Powis; Peter W Mathieson; Paul E Brenchley; Robert Kleta; Jack F M Wetzels; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

2.  Comparison of biomarkers between PLA2RAb+ and PLA2RAb- in patients with idiopathic membranous nephropathy.

Authors:  Chunhua Xun; Lihua shuai; Wenjuan Wang; Yongqing Jiang
Journal:  Int Urol Nephrol       Date:  2015-03-27       Impact factor: 2.370

3.  Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues.

Authors:  Julia M Hofstra; Jack F M Wetzels
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

Review 4.  Treatment of idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Fernando C Fervenza; Jack F M Wetzels
Journal:  Nat Rev Nephrol       Date:  2013-07-02       Impact factor: 28.314

5.  Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy.

Authors:  Yan-Ni Wang; Hao-Yu Feng; Xin Nie; Ya-Mei Zhang; Liang Zou; Xia Li; Xiao-Yong Yu; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

Review 6.  Membranous nephropathy: from models to man.

Authors:  Laurence H Beck; David J Salant
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 7.  The role of complement in membranous nephropathy.

Authors:  Hong Ma; Dana G Sandor; Laurence H Beck
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

8.  Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Hanna Debiec; Colin D Short; Timotheé Pellé; Robert Kleta; Peter W Mathieson; Pierre Ronco; Paul E Brenchley; Jack F Wetzels
Journal:  J Am Soc Nephrol       Date:  2012-09-06       Impact factor: 10.121

9.  Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.

Authors:  Anneke P Bech; Julia M Hofstra; Paul E Brenchley; Jack F M Wetzels
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-17       Impact factor: 8.237

10.  An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.

Authors:  Astrid Behnert; Marvin J Fritzler; Beina Teng; Meifeng Zhang; Frank Bollig; Hermann Haller; Andrej Skoberne; Michael Mahler; Mario Schiffer
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.